Skip to main content
Erschienen in: International Journal of Hematology 3/2024

01.02.2024 | Original Article

Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma

verfasst von: Masato Yanagi, Makiko Mori, Mamoru Honda, Yuichi Mitani, Masafumi Seki, Kohei Fukuoka, Koichi Oshima, Yuki Arakawa, Katsuyoshi Koh

Erschienen in: International Journal of Hematology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Therapy for relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in children is challenging, and new treatment methods are needed. We retrospectively analyzed eight patients with r/r T-ALL (five patients) and T-LBL (three patients) who were treated with nelarabine (NEL) plus etoposide, cyclophosphamide, and intrathecal therapy, administered 3 days apart. Five patients achieved a complete response, and the other three achieved a partial response (PR). All patients underwent hematopoietic stem cell transplantation (HSCT) after two cycles of treatment, except for one patient who received one cycle. Three patients who had previously received HSCT were treated with reduced-intensity conditioning regimens, including fludarabine, melphalan, and NEL; one survived for over 5 years after the second HSCT. Grade 2 neuropathy occurred in one patient, but other severe toxicities commonly associated with NEL were not observed during NEL administration in combination with chemotherapy. The 2-year overall survival and event-free survival rates were 60.0% and 36.5%, respectively. The addition of NEL to reinduction chemotherapy was useful in achieving remission and did not lead to excessive toxicity. In addition, a conditioning regimen, including NEL, appeared to be effective in patients who had previously undergone HSCT.
Literatur
1.
Zurück zum Zitat Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52.CrossRefPubMed Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52.CrossRefPubMed
2.
Zurück zum Zitat Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013;162(5):606–20.CrossRefPubMed Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013;162(5):606–20.CrossRefPubMed
3.
Zurück zum Zitat Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.CrossRefPubMedPubMedCentral Pui CH, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938–48.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Teachey DT, O’Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood. 2020;135(3):159–66.CrossRefPubMedPubMedCentral Teachey DT, O’Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood. 2020;135(3):159–66.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30:1663–9.CrossRefPubMedPubMedCentral Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012;30:1663–9.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children’s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in lymphoblastic leukemia. J Clin Oncol. 2020;38:3282–93.CrossRefPubMedPubMedCentral Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children’s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in lymphoblastic leukemia. J Clin Oncol. 2020;38:3282–93.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Burkhardt B, Mueller S, Khanam T, Perkins SL. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Br J Haematol. 2016;173:554–9.CrossRef Burkhardt B, Mueller S, Khanam T, Perkins SL. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Br J Haematol. 2016;173:554–9.CrossRef
8.
Zurück zum Zitat Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin–Frankfurt–Muenster group. Ann Hematol. 2009;27:3363–9. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin–Frankfurt–Muenster group. Ann Hematol. 2009;27:3363–9.
9.
Zurück zum Zitat Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia. 2015;29:1648–55.CrossRefPubMed Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia. 2015;29:1648–55.CrossRefPubMed
10.
Zurück zum Zitat Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol. 2008;27:377–84.CrossRefPubMed Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM study group. J Clin Oncol. 2008;27:377–84.CrossRefPubMed
12.
Zurück zum Zitat Shewach DS, Daddona PE, Ashcraft E, Mitchell BS. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. 1985;45(3):1008–14.PubMed Shewach DS, Daddona PE, Ashcraft E, Mitchell BS. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. 1985;45(3):1008–14.PubMed
13.
Zurück zum Zitat Rodriguez CO Jr, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003;102:1842–8.CrossRefPubMed Rodriguez CO Jr, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003;102:1842–8.CrossRefPubMed
14.
Zurück zum Zitat Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children’s oncology group. J Clin Oncol. 2005;23:3376–82.CrossRefPubMed Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the children’s oncology group. J Clin Oncol. 2005;23:3376–82.CrossRefPubMed
15.
Zurück zum Zitat Gandhi V, Tam C, O’Brien S, Jewell RC, Rodriguez CO Jr, Lerner S, et al. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008;26:1098–105.CrossRefPubMed Gandhi V, Tam C, O’Brien S, Jewell RC, Rodriguez CO Jr, Lerner S, et al. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008;26:1098–105.CrossRefPubMed
16.
Zurück zum Zitat Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol. 2017;179:284–93.CrossRefPubMed Zwaan CM, Kowalczyk J, Schmitt C, Bielorai B, Russo MW, Woessner M, et al. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Br J Haematol. 2017;179:284–93.CrossRefPubMed
17.
Zurück zum Zitat Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. Am J Hematol. 2020;95:1466–72.CrossRefPubMed Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, et al. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. Am J Hematol. 2020;95:1466–72.CrossRefPubMed
18.
Zurück zum Zitat Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol. 2010;150:345–51.CrossRefPubMed Commander LA, Seif AE, Insogna IG, Rheingold SR. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br J Haematol. 2010;150:345–51.CrossRefPubMed
19.
Zurück zum Zitat Luskin MR, Ganetsky A, Landsburg DJ, Loren DJ, Porter D, Nasta SD, et al. Nelarabine, cyclophosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol. 2016;174(2):332–4.CrossRefPubMed Luskin MR, Ganetsky A, Landsburg DJ, Loren DJ, Porter D, Nasta SD, et al. Nelarabine, cyclophosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol. 2016;174(2):332–4.CrossRefPubMed
20.
Zurück zum Zitat Kumamoto T, Goto H, Ogawa C, Hori T, Deguchi T, Araki T, et al. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan children’s cancer group. Int J Hematol. 2020;112:720–4.CrossRefPubMed Kumamoto T, Goto H, Ogawa C, Hori T, Deguchi T, Araki T, et al. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan children’s cancer group. Int J Hematol. 2020;112:720–4.CrossRefPubMed
21.
Zurück zum Zitat Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008–002 NECTAR). Pediatr Blood Cancer. 2022;69: e29901.CrossRefPubMed Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, et al. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008–002 NECTAR). Pediatr Blood Cancer. 2022;69: e29901.CrossRefPubMed
22.
Zurück zum Zitat Abaza Y, Kantarjian HM, Faderl S, Jabbour E, Jain N, Thomas D, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018;93:91–9.CrossRefPubMed Abaza Y, Kantarjian HM, Faderl S, Jabbour E, Jain N, Thomas D, et al. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018;93:91–9.CrossRefPubMed
23.
Zurück zum Zitat Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.CrossRefPubMedPubMedCentral Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
25.
Zurück zum Zitat Morita K, Jain N, Kantarjian H, Taahashi K, Fang H, Konopleva M, et al. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021;96:589–98.CrossRefPubMed Morita K, Jain N, Kantarjian H, Taahashi K, Fang H, Konopleva M, et al. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021;96:589–98.CrossRefPubMed
26.
Zurück zum Zitat Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18(2):340–7.CrossRefPubMed Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000;18(2):340–7.CrossRefPubMed
27.
Zurück zum Zitat Kato M, Ishida H, Koh K, Inagaki J, Kato K, Goto H, et al. Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: a study from the pediatric ALL working group of the Japan society for hematopoietic cell transplantation. Pediatr Blood Cancer. 2015;62:1844–50.CrossRefPubMed Kato M, Ishida H, Koh K, Inagaki J, Kato K, Goto H, et al. Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: a study from the pediatric ALL working group of the Japan society for hematopoietic cell transplantation. Pediatr Blood Cancer. 2015;62:1844–50.CrossRefPubMed
28.
Zurück zum Zitat Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55(15):3352–6.PubMed Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55(15):3352–6.PubMed
29.
Zurück zum Zitat Gandhi V, Plunkett W, Rodriguez CO Jr, Nowak BJ, Du M, Kisor M, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998;16:3607–15.CrossRefPubMed Gandhi V, Plunkett W, Rodriguez CO Jr, Nowak BJ, Du M, Kisor M, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998;16:3607–15.CrossRefPubMed
30.
Zurück zum Zitat Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO Jr, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142–52.CrossRefPubMed Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO Jr, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001;19:2142–52.CrossRefPubMed
Metadaten
Titel
Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma
verfasst von
Masato Yanagi
Makiko Mori
Mamoru Honda
Yuichi Mitani
Masafumi Seki
Kohei Fukuoka
Koichi Oshima
Yuki Arakawa
Katsuyoshi Koh
Publikationsdatum
01.02.2024
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Hematology / Ausgabe 3/2024
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-023-03701-z

Weitere Artikel der Ausgabe 3/2024

International Journal of Hematology 3/2024 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.